Second front in PBM investigation
Executive Summary
The Tennessee Attorney General's Office has requested information from Merck-Medco "similar to that requested by" the U.S. Attorney in Philadelphia as part of an investigation of pharmacy benefit management practices, the Merck-Medco initial public offering prospectus states. The Philadelphia investigation began in 1998, and Medco was subpoenaed in 1999. A second subpoena was recently issued to Schering-Plough as part of the case, but Medco was not subpoenaed again (1"The Pink Sheet" April 1, p. 32)...
You may also be interested in...
Schering, Pfizer Responding To Investigations Of Managed Care Deals
Schering-Plough is responding to a grand jury subpoena issued in March by the Philadelphia U.S. Attorney's Office focusing on whether "nominally priced" products and other free goods should have been included in Medicaid rebate calculations
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.